Prioritization for liver transplantation: Reconsidering survival benefit
Andrew P. Keaveny, C. Burcin Taner – 13 February 2017
Patient understanding of hepatocellular carcinoma surveillance
Matthew A. Goldsworthy, Ian A. Rowe – 13 February 2017
Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis
Raquel Yotti, Cristina Ripoll, Yolanda Benito, Maria Vega Catalina, Jaime Elízaga, Diego Rincón, Francisco Fernández‐Avilés, Javier Bermejo, Rafael Bañares – 13 February 2017 – An accurate evaluation of cardiac function in patients with cirrhosis remains a challenge. We used robust echocardiographic indices to characterize left ventricular (LV) systolic function and its relationship to activation of the sympathetic nervous system and inflammation in 59 patients with cirrhosis and 59 age‐matched controls.
MR lymphography of hepatic lymphatic system
Lionel Arrivé, Sanaâ Mouhadi – 13 February 2017
Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis
Guofeng Chen, Cheng Wang, Jing Chen, Dong Ji, Yudong Wang, Vanessa Wu, Johan Karlberg, George Lau – 13 February 2017 – There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients coinfected with HBV treated with pan‐oral direct‐acting antiviral agents (DAAs).
Galectin‐9: Diverse roles in hepatic immune homeostasis and inflammation
Lucy Golden‐Mason, Hugo R. Rosen – 13 February 2017 – Glycan‐binding proteins, which include galectins, are involved at all stages of immunity and inflammation, from initiation through resolution. Galectin‐9 (Gal‐9) is highly expressed in the liver and has a wide variety of biological functions in innate and adaptive immunity that are instrumental in the maintenance of hepatic homeostasis. In the setting of viral hepatitis, increased expression of Gal‐9 drives the expansion of regulatory T cells and contraction of effector T cells, thereby favoring viral persistence.
Futility of care in patients with acute‐on‐chronic liver failure
Filipe S. Cardoso, Rui Pereira, Gonçalo Alexandrino, Luís Bagulho – 13 February 2017
Risk of end‐stage liver disease, hepatocellular carcinoma, and liver‐related death by fibrosis stage in the hepatitis C Alaska Cohort
Dana J.T. Bruden, Brian J. McMahon, Lisa Townshend‐Bulson, Prabhu Gounder, Jim Gove, Julia Plotnik, Chriss Homan, Annette Hewitt, Youssef Barbour, Philip R. Spradling, Brenna C. Simons, Susan McArdle, Michael Bruce – 13 February 2017 – Long‐term prospective studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical for assessing the potential impact of HCV treatment.
Characterization of ferroptosis in murine models of hemochromatosis
Hao Wang, Peng An, Enjun Xie, Qian Wu, Xuexian Fang, Hong Gao, Zhuzhen Zhang, Yuzhu Li, Xudong Wang, Jiaying Zhang, Guoli Li, Lei Yang, Wei Liu, Junxia Min, Fudi Wang – 13 February 2017 – Ferroptosis is a recently identified iron‐dependent form of nonapoptotic cell death implicated in brain, kidney, and heart pathology. However, the biological roles of iron and iron metabolism in ferroptosis remain poorly understood. Here, we studied the functional role of iron and iron metabolism in the pathogenesis of ferroptosis.
Galectin‐9: Diverse roles in hepatic immune homeostasis and inflammation
Lucy Golden‐Mason, Hugo R. Rosen – 13 February 2017 – Glycan‐binding proteins, which include galectins, are involved at all stages of immunity and inflammation, from initiation through resolution. Galectin‐9 (Gal‐9) is highly expressed in the liver and has a wide variety of biological functions in innate and adaptive immunity that are instrumental in the maintenance of hepatic homeostasis. In the setting of viral hepatitis, increased expression of Gal‐9 drives the expansion of regulatory T cells and contraction of effector T cells, thereby favoring viral persistence.